Original Article | Published:

Clinical Pharmacology

Effect of MDR1 gene polymorphism on progression of end-stage renal disease

Acta Pharmacologica Sinica volume 28, pages 579583 (2007) | Download Citation

Project supported by the National Natural Science Foundation of China (No 30271526) and the Foundation for the Author of National Excellent Doctoral Dissertation of China (No 200368).

Abstract

Aim:

P-glycoprotein is localized at the apical brush-border membrane of the proximal renal tubule and functions as extruding toxins and xenobiotics out of cells. The difference of P-glycoprotein's function resulted from single nucleotide polymorphisms in MDR1 (multidrug resistance gene encoding for P-gp) and may be the cause of interindividual differences in susceptibility to end-stage renal disease (ESRD). The purpose of this study is to compare the genotype frequency of C3435T and G1199A polymorphisms in MDR1 between ESRD patients and healthy controls in the Chinese population to determine whether the alteration of the P-gp function is associated with ESRD.

Methods:

Two hundred and eighty-four healthy Chinese controls and 244 Chinese patients with ESRD were involved in this study. Allele specific PCR and polymerase chain reaction-restriction fragment length polymorphism assay were used to determine the genotype MDR1 G1199A and C3435T, respectively.

Results:

The genotype distribution of 3435CC, 3435CT, and 3435TT were 0.35, 0.50, and 0.15, respectively, in the control group and 0.38, 0.47, and 0.15 in the group with the ESRD patients. No variant allele 1199G>A was found in any of the patients. The value of serum creatinine for genotypes 3435CC, 3435CT, and 3435TT in the ESRD patients were 753.8±276.0 μmol/L, 849.6±342.2 μmol/L, and 987.0±512.0 μmol/L, respectively. The difference between 3435TT and 3435CC reached statistical significance (P<0.05).

Conclusion:

The low expression of P-glycoprotein was not the etiological factor for the kidney disease, but it may contribute to the progression of ESRD and affect the severity. Chinese people do not carry the 1199G>A variant allele. More studies are needed to clarify the cause and interindividual differences in the susceptibility for the risk of ESRD.

References

  1. 1.

    , , , , , , Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–8.

  2. 2.

    , , , , , et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–8.

  3. 3.

    , , , , , et al. Role for ‘uremic toxin’ in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461–9.

  4. 4.

    , , , , , et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598–604.

  5. 5.

    , Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43: S106–10.

  6. 6.

    , , , , Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97–103.

  7. 7.

    , , , , , , The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 52: S23–8.

  8. 8.

    , , , , , et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749–56.

  9. 9.

    , , , , , et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–8.

  10. 10.

    , , , , , et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847–54.

  11. 11.

    , , , , , Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659–65.

  12. 12.

    , , , , , Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 2004; 310: 1199–207.

  13. 13.

    , Practice of internal medicine. 12th ed. Beijing: People's Medical Publishing House.

  14. 14.

    , , , Sequence diversity and haplotype structure in the human ABCB1(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481–94.

  15. 15.

    , , , , , et al. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin Chim Acta 2005; 359: 46–52.

  16. 16.

    , , , , , et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 2006; 46: 373–9.

  17. 17.

    , , , , , et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297–303.

  18. 18.

    , , , , , et al. SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy. Diabetes 2006; 55: 843–8.

  19. 19.

    , , , , Interleukin-1 beta and receptor antagonist (IL-1Ra) gene polymorphisms and the prediction of the risk of end-stage renal disease. Biomarkers 2006; 11: 164–73.

  20. 20.

    , , , , , et al. Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Hellens from Greece and Cyprus. Genet Test 2004; 8: 319–24.

  21. 21.

    , , , , , , The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 2005; 24: 287–94.

  22. 22.

    , , , , , et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169–74.

Download references

Author information

Affiliations

  1. Institute of Clinical Pharmacology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

    • Wei-xia Zhang
    • , Bing Chen
    • , Zi-cheng Yu
    •  & Wei-min Cai
  2. Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

    • Wen Zhang
    •  & Nan Chen

Authors

  1. Search for Wei-xia Zhang in:

  2. Search for Bing Chen in:

  3. Search for Wen Zhang in:

  4. Search for Nan Chen in:

  5. Search for Zi-cheng Yu in:

  6. Search for Wei-min Cai in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1745-7254.2007.00517.x

Further reading